Sargramostim

Therapeutic indications

Sargramostim is indicated for:

Acute myeloid leukemia

Population group: only adults (18 years old or older)

Acute myeloid leukemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Peripheral blood progenitor cell transplantation

Population group: only adults (18 years old or older)

Myeloid reconstitution is further accelerated by administration of sargramostim following peripheral blood progenitor cell transplantation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Autologous bone marrow transplant

Population group: only adults (18 years old or older)

Autologous bone marrow transplant

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Allogeneic bone marrow transplantation

Population group: only adults (18 years old or older)

Allogeneic bone marrow transplantation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈